Evidence mapPaperPMID 39475941Full record

ArticlePloS one2024

Characterization of patients with Duchenne muscular dystrophy across previously developed health states.

Francesco Muntoni, Nathalie Goemans, Nate Posner, James Signorovitch, Michaela Johnson, Chujun He, Patricia Dorling, Katherine Beaverson, Jose Alvir, Matthias Mahn and 4 more

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Francesco MuntoniDubowitz Neuromuscular Centre, Great Ormond Street Institute of Child Health, London, United Kingdom.
Nathalie GoemansUniversity Hospitals Leuven, Child Neurology, Leuven, Belgium.
Nate PosnerPfizer, Inc., New York, NY, United States of America.
James SignorovitchAnalysis Group, Inc., Boston, MA, United States of America.ORCID https://orcid.org/0000-0002-4067-8962
Michaela JohnsonAnalysis Group, Inc., Boston, MA, United States of America.
Chujun HeAnalysis Group, Inc., Boston, MA, United States of America.
Patricia DorlingChiesi USA, Inc. Boston, MA, United States of America.
Katherine BeaversonPfizer, Inc., New York, NY, United States of America.
Jose AlvirPfizer, Inc., New York, NY, United States of America.
Matthias MahnPfizer, Inc., New York, NY, United States of America.ORCID https://orcid.org/0000-0002-1629-9372
Susan J Wardcollaborative Trajectory Analysis Project (cTAP), Cambridge, MA, United States of America.
Craig M McDonaldDepartment of Physical Medicine and Rehabilitation, University of California, Davis, Sacramento, CA, United States of America.
Eugenio MercuriPediatric Neurology, Catholic University, Rome, Italy.
PRO-DMD-01 study, the Imaging DMD study, iMDEX, the collaborative Trajectory Analysis Project (cTAP)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Project HERCULES has developed a natural history model (NHM) of disease progression in Duchenne muscular dystrophy (DMD) that comprises eight ordered health states (two ambulatory states, one transfer state indicating increased caregiver burden in which patients cannot walk/run 10m or rise from floor but can still support their own weight, and five non-ambulatory states). The current study used data from nine sources (clinical trial placebo arms, one real-world dataset, and three natural history datasets) to further characterize patients with DMD according to these health states. The study included 1,173 patients across 5,306‬ visits. Patients were on average older and exhibited worse ambulatory, pulmonary, upper limb, and cardiac functions with each successive health state. Mean±SE ages increased monotonically across health states, starting with 8.47±0.07 for early ambulatory, 10.86±0.13 for late ambulatory, 11.65±0.35 for transfer state, and ranging from 13.17±0.32 to 16.84±0.37 for the non-ambulatory states. North Star Ambulatory Assessment (NSAA) total score, which measures motor function and ranges from 34 (best) to 0 (worst), was 23.7 (interquartile range [IQR]: 20-30) for early ambulatory patients, 12.7 (IQR: 9-16) for late ambulatory patients, and 3.9 (IQR: 2-5) for transfer patients. Pulmonary function as measured by mean±SE of forced vital capacity percent predicted (FVC%p) was 94.5±0.8 for early ambulatory, 89.1±1.4 for late ambulatory, and 80.2±2.8 for transfer states, and decreased from 77.2±1.7 to 20.6±1.6 across the five non-ambulatory health states. In summary, these findings further characterize health states and their interpretation in economic modeling and decision-making in DMD management.

Indexed as

Muscular Dystrophy, DuchenneAdolescentChildChild, PreschoolDisease ProgressionFemaleHealth StatusHumansMaleWalking

Identifiers

PMID39475941
PMCPMC11524485

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.